Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.

被引：1
|
作者：
Calegari, Maria Alessandra
Orlandi, Armando
Indellicati, Giulia
Martini, Maurizio
Cocomazzi, Alessandra
Bagala, Cinzia
Zurlo, Valeria
Di Dio, Carmela
Barile, Rosalba
Monterisi, Santa
Cassano, Alessandra
Astone, Antonio
Barone, Carlo
机构：
[1] Policlin Univ A Gemelli, UOC Oncol Med, Rome, Italy
[2] Policlin Univ A Gemelli, Ist Anat Patol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15295
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [42] A Study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma
    Mahalingam, D.
    Wang, Y.
    Lu, T. W.
    Sarantopoulos, J.
    Vemulapalli, S.
    Aparo, S.
    Coffey, M.
    Gill, G.
    Kennealey, G.
    Mita, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 170 - 171
  • [43] Prognostic Value of hENT-1 in Patients with Resected Pancreatic Adenocarcinoma
    Lai, K. K.
    Tan, A.
    Kim, R. D.
    Jiang, J.
    Wang, Y.
    Rybicki, L. A.
    Liu, X.
    LABORATORY INVESTIGATION, 2010, 90 : 360A - 360A
  • [44] FOLFIRINOX for locally advanced and metastatic pancreatic ductal adenocarcinoma
    Hisai, Hiroyuki
    Tamaki, Sakurai
    Yuuki, Ikeda
    Yutaka, Koshiba
    Masafumi, Sato
    Ryosuke, Kawasaki
    Hiroshi, Gyobu
    Etsu, Miyazaki
    Tasuku, Hirako
    Shogo, Miura
    ANNALS OF ONCOLOGY, 2015, 26 : 120 - 120
  • [45] Comparison of systematic inflammatory prognostic scores in patients with advanced pancreatic adenocarcinoma.
    Ma, Lucy Xiaolu
    Espin-Garcia, Osvaldo
    Wang, Yifan
    Allen, Michael J.
    Jang, Gun Ho
    Zhang, Amy
    Dodd, Anna
    Ramotar, Stephanie
    Hutchinson, Shawn
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James Joseph
    Wilson, Julie
    Notta, Faiyaz
    Fischer, Sandra
    Zogopoulos, George
    Gallinger, Steven
    Grant, Robert C.
    Knox, Jennifer J.
    O'Kane, Grainne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
    Mortier, Victor
    Wei, Felix
    Pellat, Anna
    Marchese, Ugo
    Dohan, Anthony
    Brezault, Catherine
    Barat, Maxime
    Fuks, David
    Soyer, Philippe
    Coriat, Romain
    CANCERS, 2022, 14 (24)
  • [47] Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer.
    Wolfe, Adam R.
    Miller, Eric David
    Abushahin, Laith I.
    Cloyd, Jordan
    Manilchuck, Adrei
    Dillhoff, Mary
    Pardo, Dayssy Alexandra Diaz
    Noonan, Anne M.
    Williams, Terence M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Schultheis, Beate
    Strumberg, Dirk
    Kuhlmann, Jan
    Wolf, Martin
    Link, Karin
    Seufferlein, Thomas
    Kaufmann, Joerg
    Gebhardt, Frank
    Bruyniks, Nico
    Pelzer, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [49] Clinical and pharmacokinetic study of gemcitabine (GEM) - oxaliplatin (OXA) association in metastatic or locally advanced pancreatic adenocarcinoma.
    Airoldi, M
    Cattel, L
    Passera, R
    Micari, C
    Ferrarato, E
    Zanon, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 141S - 141S
  • [50] PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma.
    Rivera, Fernando
    Gallego, Javier
    Guillen Ponce, Carmen
    Benavides, Manuel
    Lopez-Martin, Jose A.
    Kueng, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345